MK-3134 + scopolamine

MK-3134 is a small molecule drug developed by Merck that acts as an inverse agonist at the histamine H3 receptor, a presynaptic autoreceptor in the central nervous system involved in regulating neurotransmitter release. It has been investigated for its potential to improve cognition, particularly in conditions such as dementia and cognitive dysfunction. Scopolamine is an anticholinergic agent used primarily to prevent nausea and vomiting from motion sickness or anesthesia, but also for gastrointestinal disorders and Parkinson-like conditions. The combination of MK-3134 with scopolamine has been studied experimentally to assess whether inverse agonism of the H3 receptor can attenuate cognitive impairment induced by cholinergic blockade (as caused by scopolamine). Clinical studies suggest that MK-3134 may provide some improvement in cognition when administered alongside or after scopolamine-induced impairment, supporting possible cooperation between histaminergic and cholinergic systems[2][3][5][7].

Brand names

Maldemar (for scopolamine)

Other names

D8A4Z52D1J (for MK-3134)